Classification
Most PIDs are caused by mutations in single genes but the variable penetrance of these mutations results in diverse phenotypes and severity, which makes recognition and differential diagnosis difficult. [3, 4] Owing to this complexity, the International Union of Immunological Societies (IUIS) Expert Committee on Primary Immunodeficiency has developed a classification for PID with the goal of facilitating diagnosis and treatment. According to the last updated report in 2015, PIDs are categorised into nine major groups ( Table 1 ). [5] Clinical manifestations Individuals suffering from PIDs are more prone to recurrent and chronic infections with a number of different infectious agents, which cause significant morbidity and mortality. Although impairment of immune function can affect various organs, the most common sites of infection are the sinopulmonary system and the gastrointestinal tract. While unusual organisms generally cause these infections, typical infections that are atypical in length and severity are more often observed and may lead to lethal outcomes. In addition to susceptibility to infections, a poorly regulated immune system in PID patients may lead to inflammation, autoimmunity and malignancy. [2] Global prevalence of PID While PIDs are individually quite rare, collectively they represent a significant burden of disease. Recent studies which have extrapolated the prevalence of PID from registry data have shown that the disease may be more common than previously estimated [6] [7] [8] [9] [10] and, in fact, it has been suggested that the prevalence and incidence of PIDs may be as high as those observed for diseases such as leukaemia. [6] To estimate the global prevalence of PID in 2013, Bousfiha et al. [6] used data from continental and national registries in specific records from the Australia/New Zealand registry [7] and two specific epidemiological surveys conducted in the USA. [8, 9] The prevalence of PIDs in different countries was extrapolated from these registries and surveys based on the populations of each country. It is estimated that as many as 6 million people may be living with a PID worldwide, [6] whereas only 27 000 -60 000 (0.45 -1%) have been registered in national registries and the Jeffrey Modell Centers Network (JMCN). Table 2 illustrates the frequency of PID worldwide as estimated in the Bousfiha et al. [6] study.
In an attempt to report all PID cases diagnosed worldwide since 2013, the Jeffrey Modell Foundation (JMF) has launched an annual survey in 358 institutions within the JMCN, covering 86 countries on 6 continents. In its latest report in 2018, JMF indicated that 187 988 PID patients were being followed globally. A total of 94 024 were identified as having a specific named PID. [10] According RESEARCH to this report, the subgroup 'predominantly antibody deficiencies' comprising 45% of the PID patients identified is the leading global PID followed by 'combined immunodeficiency with associated or syndromic features' in 13% of patients. This study also showed that some PIDs are more common in certain geographic areas than others. [10] As seen above, different studies have generated inconsistent results. Moreover, worldwide data registries are not able to provide full coverage of PID patients at the present time. Therefore, the identification of PID patients is confronted by an underreporting bias. Regardless of these challenges, PIDs are clearly more common than generally thought.
Diagnosis
There is a lack of awareness of PIDs among the public and healthcare workers, resulting in delays in diagnosis. On the other hand, an important issue affecting patient outcomes is the time interval between the onset of symptoms and making a diagnosis. Therefore, early diagnosis is critical to prevent significant morbidity and mortality. In order to raise the index of suspicion among healthcare professionals and patients, the medical advisory board of the JMF identified 10 warning signs of PID (http://www.info4pi.org/aboutPI/ pdf/General10WarningSignsFINAL.pdf) ( Table 3 ). Knowing these warning signs helps physicians to identify patients suitable for appropriate immunological evaluation. [2, 14] The IUIS PID expert committee has also recently developed a phenotypic classification, which through nine algorithms helps clinicians with bedside diagnosis of PIDs. [15] Once an immunodeficiency is suspected, a thorough history and physical examination will further direct the initial workup for screening of the immune system. If the result of the initial evaluation is positive, further testing will be done. The definite diagnosis of a PID which is important for the management of patients and further genetic counseling is reached by molecular diagnosis. [16] However, despite scientific progress in the field, there are still inadequate laboratory resources and diagnostic methods in many countries. [17] In fact, variations observed in the number of cases reported from country to country could often be related to the lack of access to appropriate laboratory testing. [18] Treatment Most PIDs are chronic diseases and, once recognised, patients require specific care for the rest of their lives. However, the treatment of PID is complex and generally requires both supportive and definitive Table 1 . Classification of PID from the IUIS Expert Committee for Primary Immunodeficiency [5] 1
Immunodeficiencies affecting cellular and humoral immunity (e.g. SCID) 2
Combined immunodeficiency with Associated or Syndromic Features (e.g. WAS, ataxia-telangiectasia) 3 Predominantly antibody deficiencies (e.g. agammaglobunaemia) 4
Diseases of immune dysregulation (e.g. Chediak-Higashi syndrome) 5
Congenital defects of phagocyte number function or both (e.g. LAD1) 6
Defects in intrinsic and innate immunity (e.g. MSMD) 7
Autoinflammatory disorders (e.g. familial Mediterranean fever) 8 Complement deficiencies (e.g. complement cascade component deficiencies) 9
Phenocopies of PID (e.g. autoimmune lymphoproliferative syndrome) PID = primary immunodeficiency; SCID = severe combined immunodeficiency; WAS = Wiskott-Aldrich syndrome; LAD1 = leukocyte adhesion deficiency type 1; MSMD = Mendelian susceptibility to mycobacterial disease. 
Region
Estimate of the number of PID patients based on a prevalence of 5.6/100 000 inhabitants from the Australian Registry [7] Estimate of the number of PID patients based on a prevalence of 86.3/100 000 inhabitants from the Boyle and Buckley's survey [8] Estimate of the annual incidence of PID based on an incidence of 10.3/100 000 person years from Joshi et al. [ Recurrent deep skin or organ abscesses (e.g. liver, lungs) 7
Persistent thrush in mouth or fungal infection on skin 8
Need for intravenous antibiotics to clear infections 9
>2 deep seated infections (e.g. septicaemia, meningitis) 10
Family history of a PID PID = primary immunodeficiency.
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approaches carried out by a multidisciplinary team. Initial therapy for most patients is supportive and involves aggressive management of the infection, immunoglobulin (Ig) replacement therapy, and antibiotic and antifungal prophylaxis. Ig replacement therapy has proven to increase the survival rates and decrease the frequency of life-threatening infections, especially pneumonia in antibodydeficient patients. [20] [21] [22] According to the 2018 JMF survey, 23 967 patients were receiving Ig therapy worldwide. [10] While cytokine-and enzyme-replacement therapy are other treatment modalities for some of these patients, haematopoietic stem cell transplantation (HSCT) and gene therapy could be considered as the definitive cure for a group of more severe PIDs, such as severe combined immunodeficiency (SCID). [19, 23, 24] An allogeneic HSCT involves the intravenous infusion of allogeneic haematopoietic stem cells into the recipient's body usually after preparation of the recipient with a conditioning regimen, which permits some degree of donor cell engraftment and replacement of lymphohaematopoietic function. [26] This procedure was first performed in 1968 on a 22-month-old male infant suffering from SCID. [25] In the past 45 years, there have been great advances in the field of HSCT. [26] The remarkable improvements in allogeneic HSCT, despite the limitations of HSCT, e.g. the lack of human leukocyte antigen (HLA)-compatible donors and also complications such as graft-versus-host disease (GVHD), have increased interest in gene therapy for treating PID patients. [19] Gene therapy was first introduced in the early 1990s. [28, 29] In this approach, a normal copy of the mutated and disease-related gene of the PID patient is introduced into the patient's stem cells ex vivo using a viral vector, following which the transduced cells are transplanted back into the patient's body. [19] Given the fact that disease-related genes have now been found for most PIDs, gene therapy may become an important treatment option for many of these conditions. However, gene therapy runs the risk of insertional mutagenesis which is dependent on the nature of the technology used, such as gene editing and the type of vector. [31] In 2018, the JMF reported on the total number of patients worldwide who had received HSCT or gene therapy: 4 421 and 181 patients, respectively. [10] 
Methodology
In this review, we evaluated all studies published from the African continent in the field of PID regarding prevalence, epidemiology, case reports and genetic findings. To this end, we performed a literature search in PubMed using the keywords 'prevalence' , 'incidence' , 'primary immunodeficiency' , 'genetic mutations' and ' Africa' . We excluded studies on immunodeficiency due to human immunodeficiency virus (HIV) by using the keyword 'not HIV' . In our search we had no filter regarding the year of publication of the articles. We identified many African studies on different aspects of PID from the northern and southern regions of the continent. We found only one study from western Africa but no studies from eastern or central Africa. However, it should be cautioned that findings from northern and southern Africa cannot necessarily be extrapolated to other regions on the African continent.
Results
When compared with other continents, Africa has experienced a delay with regard to PID diagnosis and care. However, with the establishment of the African Society for Immunodeficiencies (ASID; www.asid.ma) in Casablanca (Morocco) in 2008, there has been an increase in awareness on the continent of PIDs among physicians and the general public. Moreover, ASID has begun to collect data from PID patients for the purpose of creating an international registry.
In recent years, different regions of the African continent have also been involved in hosting international congresses and workshops on PID and collaborating with experts from various parts of the world. [32] In fact, the regions of North Africa and the Middle East have joined efforts by hosting 'The Middle East and North Africa Immunodeficiency' (MENAID) meetings; it is hoped that this will help to improve the quality of life of patients with PID. What both regions have in common is their high prevalence of consanguineous marriages (20 -60%) which results in a higher incidence of autosomal recessive PIDs. [32, 33] Another example of a medical society in Africa that is driving the dissemination of medical information and influencing public opinion is the 'Primary Immunodeficiency Diseases South Africa' working group, which is an active Working Group of the Allergy Society of South Africa (ALLSA) and hosts annual congresses and meetings (www.allergysa.org).
Prevalence of PID on the African continent
Very few studies have been conducted in Africa which specifically describe the prevalence and epidemiological features of PIDs on the continent. Those that have been conducted are shown in Table 4 . [35] [36] [37] [38] [39] [40] In the latest JMF global survey, 1 836 patients with PIDs out of a global total of 94 024 were from Africa. [10] Africa is the second most populous continent, suggesting that it should have a larger number of PID cases, yet its registry contains the smallest proportion of cases. Bousfiha et al. [6] estimated the prevalence of PID to be 902 631 cases in Africa. The exact prevalence of PID on the African continent remains unknown.
Barbouche et al. [33] investigated the prevalence of PID in northern Africa by collecting data from PID referral clinics in Morocco, Egypt and Tunisia and found that the most prevalent immunodeficiency reported from Egypt and Tunisia was combined immunodeficiency (41% v. 27%), while that from Morocco was combined immunodeficiency with associated or syndromic features (34%). The authors concluded that the hallmark of their North African PID cohort was the high rate of autosomal recessive PIDs compared with the European Registry which is aligned with the high frequency of parental consanguinity in the region.
Novel mutations in the African population
Many studies in the northern region of Africa describe an autosomal recessive transmission mode for PIDs and some have reported novel autosomal recessive gene mutations. [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] Due to this fact, the northern region of Africa seems to be a distinctive epidemiological area for the study of genetic diseases, such as PIDs, which has drawn the attention of many researchers in the past decade. Table 5 illustrates some of the studies describing molecular characterisation, novel genetic mutations and founder effects of PIDs undertaken mainly in Africa.
Autosomal recessive PIDs are particularly frequent in North African populations, and a strong founder effect for specific mutations in PIDs has been reported. For example, the major histocompatibility complex (MHC) class II combined immunodeficiency has been described mainly in patients living in or originating from North African countries (predominantly the Maghrebian countries, i.e. Morocco, Algeria and Tunisia). Therefore, it has been considered to be a 'Maghrebian disease' . In fact, several studies have reported a founder effect for the RFXANK gene mutation 752delG26 in these patients. [46, 48, 49, 55, 59] In 2011, Ouederni et al. [55] dated the founder event responsible for this mutation in this population to ~2 250 years ago. A study by Ben-Mustapha et al. [44] in 2014 reported a common founder Bejaoui et al. [37] Centre National de Greffe Ben-Mustapha [44] (2014) Tunisia 6 Tunisian patients MSMD Founder effect for the c.298_305del mutation in the IL12B gene Baba [45] (2014) Morocco 12 CGD Four different mutations of CYBB, a recurrent mutation of NCF1 and a new mutation of NCF2 in three patients Ben-Mustapha et al. [46] (2013) Tunisia 34 (belonging to 28 Tunisian families)
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MHC class II expression deficiency
Founder effect for the c.338-25_338del26 mutation in the RFXANK gene in 25 patients Landouré et al. [47] (2013) Mali 3 patients from 1 Malian family Ataxia-telangiectasia Novel c.7985T > A mutation in ATM gene Djidjik et al. [48] (2012) Algeria 11 Algerian patients MHC class II expression deficiency Founder effect for the 752delG26 mutation in RFXANK gene in 9 patients Naamane et al. [49] There are additional scattered studies from the region describing PID, including patients' susceptibilities to various infections and case reports. [61] [62] [63] [64] [65] [66] [67] [68] 
Diagnosis of PID on the African continent
Although basic laboratory tests are available for the diagnosis of PID in some African countries, there are still limitations with regard to specialised immunological and genetic tools required for more accurate investigations. Particular laboratory tests, e.g. specific antibodies (IgG subclasses) lymphocyte subpopulations and proliferation studies, and functional phagocyte tests, are only available in a very limited number of referral centres.
With respect to molecular studies, many centres on the continent are in the early phases of development, with limited capacity for genetic diagnosis of some PIDs. There has been a recent drive in African referral centres to expand molecular diagnostic services for PID, which includes polymerase chain reaction (PCR) analysis of T-cell receptor excision circles (TREC) and Kappadeleting recombination excision circles (KREC) as part of a newborn screening programme for severe PIDs. Still, most centres work in collaboration with specialised laboratories abroad for occasional definitive diagnosis of selected PID cases.
In 2016, a private diagnostic laboratory in South Africa developed a targeted next-generation sequencing (NGS) gene panel consisting of 99 of the most frequently associated PID genes. [70] The panel can be used as both a molecular confirmation and a screening tool for 18 PID phenotypes found within the nine International Union of Immunological Societies (IUIS) PID classifications (Table 1) . Furthermore, whole exome and transcriptome sequencing are currently being investigated for those more challenging cases in which clinical presentation is indicative of a PID when immunological investigations and targeted sequencing have proved uninformative. Table 6 shows the laboratory tests available for the diagnosis of PID in SA; these have been grouped into a stepwise investigative approach. All the tests indicated are available in SA and the public (government) sector has permission to refer this work to Ampath through the National Health Laboratory Services when clinically indicated. Lack of diagnostic facilities can cause delays in diagnosis and may ultimately compromise the clinical outcome of these patients. [33, 34, 36] 
Treatment options for PID in Africa
With an average mortality rate of 20% in northern and southern Africa, there are still considerable challenges in the region regarding the management and overall clinical outcome of PID patients. [34] [35] [36] [37] Generally, 40% of PID patients in these regions receive intravenous immunoglobulin (IVIG) [34, 35, 40] despite limitations in the availability of IVIG in some regions. [33] HSCT using haploidentical donors has been introduced as a treatment option in severe cases of PID but only in very few centres on the continent and with long waiting lists. [34] [35] [36] However, due to the cost morbidity and mortality associated with HSCT, clinicians are very cautious about administering gene therapy, specifically if the patient is fairly well controlled.
Gene therapy as an option in the African continent
According to the JMF global survey, there has been a significant increase in the number of patients receiving gene therapy worldwide, with the greatest number residing in Western Europe. [10] Although in 2016 the first retroviral long terminal repeat (LTR)-based vector received license for ex vivo gene therapy in SCID, many challenges still need to be overcome before gene therapy can be offered as a standard therapy for all patients. [76] To our knowledge, no centre on the African continent has performed gene therapy on PID patients to date. As the field of PIDs continues to grow and the number of children and adults diagnosed with PID in the region increases, gene therapy could become an effective treatment option for patients on the African continent in the future. [57] (2001)
France 1 North African patient MHC class II expression deficiency
Uncoordinated expression of the HLA-D genes in a new RFXANK gene mutation Altare et al. [58] (2001) France 2 siblings from North Africa MSMD Heterogeneity of the clinical phenotype associated with IL-12RB1 deficiency Wiszniewski et al. [59] (2000)
France 20 North African patients
MHC class II expression deficiency
Founder effect for the 752delG26 mutation in the RFXANK gene in 17 patients Jouanguy et al. [60] 
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In addition to the outcomes and efficacy of this form of treatment, elevated costs are a major concern. However, many believe that a onetime cure could still save money in the long-term by reducing the need for expensive care. In 2014, Buckland et al. [69] reported that the cost of an allogeneic bone marrow transplant for a patient with a primary immunodeficiency was ≥£250 000. In contrast, the manufacture of autologous gene modified CD34 + cells could be achieved at a cost of ~£15 000 -£30 000. The additional follow-up costs after gene therapy treatment for PIDs are also likely to be significantly less given that the length of hospital stay and long-term prophylactic medication requirements and other post-therapy complications are considerably reduced, compared with conventional HSCT.
Limitations regarding PID on the African continent
PID is mostly underdiagnosed in Africa and, although considerable progress has been achieved in parts of the continent, many challenges remain regarding awareness, diagnosis, registration and care of these patients.
At present, only 2 of the 54 countries on the continent have national registries: the Moroccan Society for PID (MSPID, www.pidmoroccansociety.org) and the South African National PID Registry (https://www.pinsa.org.za/). Without national registries, accurate prevalence and incidence data cannot be gathered. Participation in these networks will establish earlier diagnosis and improve treatment and clinical care, resulting in an improvement in the quality of life of these patients. There is also a need to improve public health policy in this field. [6, 33] The lack of specialised physicians in the field of clinical immunology in many areas of the African continent negatively affects the management of PID patients in the region. The training of expert clinical immunologists could assist in raising awareness of PID in the medical community. In addition, networks such as Primary Immunodeficiency Diseases Network of South Africa (PINSA) and ASID could play an important role in creating awareness of PIDs on the continent.
The burden of HIV and other epidemic illnesses, particularly in the sub-Saharan region, is likely to be a major contributor to the under-diagnosis of PID. [28] It is assumed that the expanding HIV epidemic, especially in SA, over the past 30 years has compromised clinical recognition of PID. [34] In addition to efforts aimed at increasing the awareness of PID in the region, there is a need for improvement in diagnosis. Conducting molecular and genetic studies in the region could support the future development of genetic counseling, prenatal diagnosis and gene therapy. [33] Africa faces a number of challenges, which include a paucity of diagnostic facilities, limited expertise, as well as limited financial resources. These challenges may be overcome by creating diagnostic referral centers for PID on the continent. These specialised centres could potentially offer basic as well as definitive molecular diagnostic services at a lower cost and faster turnaround time than when samples are sent to international laboratories.
Conclusion
With the exception of South and northern Africa, there appears to be limited activity in the field of PID on the African continent, resulting in lack of awareness, underdiagnoses, mismanagement and suboptimal care. Additionally, as the field of PID is continually growing, advanced therapeutic modalities are rapidly expanding worldwide and options such as gene therapy are becoming a reality.
Given the unique genetic mutations reported in PID patients on the African continent and the feasibility of HSCT and gene therapy, these new therapeutic options should be considered.
